Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICHARD SANDERS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1730142365
CMS profile
810988
Location
DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$71.88

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $71.88 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lundbeck LLC $51.90 2
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19.98 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICHARD SANDERS

NPI 1730142365 · CMS profile ID 810988

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICHARD SANDERS, NPI 1730142365, CMS profile ID 810988. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RICHARD SANDERS, NPI 1730142365, CMS profile ID 810988. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RICHARD SANDERS, NPI 1730142365, CMS profile ID 810988, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1730142365?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $71.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lundbeck LLC $22.1512/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251844047 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19.9811/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241394671 CMS
Lundbeck LLC $29.7509/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251844045 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2025 $71.88 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $725,804.81 104
PY2024 Principal investigator $563,851.77 79
PY2023 Recipient $760.01 11
PY2023 Principal investigator $543,366.08 41
PY2022 Principal investigator $672.88 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 10/16/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244048453
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,278.00 10/16/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244048455
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 09/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719283
Principal investigator 1 Indivior Inc. $65.00 09/04/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240468381
Principal investigator 1 Indivior Inc. $375.99 08/11/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240467855
Principal investigator 1 Eli Lilly and Company $4,228.12 08/08/2025 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A PHASE 1, DOUBLE-BLIND, TWO-ARM, MECHANISM OF ACTION STUDY TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON BODY COMPOSITION IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT, WITHOUT DIABETES No dispute reported 06/30/2026 1187879393
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,955.24 07/31/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244048451
Principal investigator 1 Boehringer Ingelheim International GmbH $840.00 07/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719271
Principal investigator 1 Boehringer Ingelheim International GmbH $2,200.00 07/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719273
Principal investigator 1 Boehringer Ingelheim International GmbH $1,750.00 07/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719275
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719277
Principal investigator 1 Boehringer Ingelheim International GmbH $1,100.00 07/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719279
Principal investigator 1 Boehringer Ingelheim International GmbH $616.00 07/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719281
Principal investigator 1 Indivior Inc. $6,076.66 07/24/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240467739
Principal investigator 1 Indivior Inc. $125.00 07/24/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240467741
Principal investigator 1 Indivior Inc. $7,259.33 07/03/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240467323
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 06/11/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719267
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 06/11/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719269
Principal investigator 1 Indivior Inc. $215.00 06/09/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466681
Principal investigator 1 Indivior Inc. $890.00 06/09/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466683
Principal investigator 1 Indivior Inc. $14,623.77 05/23/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466245
Principal investigator 1 Indivior Inc. $134.20 05/15/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466193
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 05/14/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719255
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 05/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719257
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 05/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719259
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 05/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719261
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 05/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719263
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 04/30/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719265
Principal investigator 1 Indivior Inc. $10,324.83 04/25/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240466033
Principal investigator 1 Eli Lilly and Company $431,671.08 04/23/2025 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A PHASE 1, DOUBLE-BLIND, TWO-ARM, MECHANISM OF ACTION STUDY TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON BODY COMPOSITION IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT, WITHOUT DIABETES No dispute reported 06/30/2026 1187881940
Principal investigator 1 Indivior Inc. $695.00 04/05/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240465627
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 04/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719247
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 04/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719249
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719251
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719253
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,809.64 04/01/2025 Non-covered Recipient Entity
ERG Holding Company LLC Woodland Internation Research Group LLC
Connex-3 No dispute reported 06/30/2026 1220802928
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 03/31/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719235
Principal investigator 1 Indivior Inc. $33,412.91 03/31/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240465171
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,093.94 03/26/2025 Non-covered Recipient Entity
ERG Holding Company LLC Woodland Internation Research Group LLC
Connex-3 No dispute reported 06/30/2026 1220802926
Principal investigator 1 Indivior Inc. $89.47 03/19/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240465028
Principal investigator 1 Indivior Inc. $1,825.00 03/19/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240465050
Principal investigator 1 Boehringer Ingelheim International GmbH $3,416.00 03/07/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719237
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 03/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719223
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 03/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719225
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719227
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719229
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 02/28/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719233
Principal investigator 1 Indivior Inc. $1,092.53 02/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240464554
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 02/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719211
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 02/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719243
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719245
Principal investigator 1 Indivior Inc. $42,172.35 02/21/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240464394
Principal investigator 1 Boehringer Ingelheim International GmbH $3,779.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719171
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719173
Principal investigator 1 Boehringer Ingelheim International GmbH $3,779.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719175
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719177
Principal investigator 1 Boehringer Ingelheim International GmbH $3,779.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719179
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719181
Principal investigator 1 Boehringer Ingelheim International GmbH $5,038.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719183
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719185
Principal investigator 1 Boehringer Ingelheim International GmbH $5,038.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719187
Principal investigator 1 Boehringer Ingelheim International GmbH $5,038.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719189
Principal investigator 1 Boehringer Ingelheim International GmbH $115.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719191
Principal investigator 1 Boehringer Ingelheim International GmbH $4,231.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719193
Principal investigator 1 Boehringer Ingelheim International GmbH $3,416.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719195
Principal investigator 1 Boehringer Ingelheim International GmbH $4,744.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719197
Principal investigator 1 Boehringer Ingelheim International GmbH $4,231.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719199
Principal investigator 1 Boehringer Ingelheim International GmbH $3,416.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719201
Principal investigator 1 Boehringer Ingelheim International GmbH $4,231.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719203
Principal investigator 1 Boehringer Ingelheim International GmbH $3,416.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719205
Principal investigator 1 Boehringer Ingelheim International GmbH $4,744.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719207
Principal investigator 1 Boehringer Ingelheim International GmbH $4,231.00 02/19/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719209
Principal investigator 1 Indivior Inc. $758.17 02/17/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240464304
Principal investigator 1 Boehringer Ingelheim International GmbH $59.00 02/07/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719169
Principal investigator 1 Boehringer Ingelheim International GmbH $10,000.00 02/07/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719213
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 02/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719215
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 02/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719217
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 02/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719219
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 02/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719221
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 01/31/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719231
Principal investigator 1 Indivior Inc. $668.71 01/29/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463735
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 01/27/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719239
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 01/27/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719241
Principal investigator 1 Indivior Inc. $6,275.27 01/22/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463403
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719139
Principal investigator 1 Boehringer Ingelheim International GmbH $480.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719141
Principal investigator 1 Boehringer Ingelheim International GmbH $5,038.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719143
Principal investigator 1 Boehringer Ingelheim International GmbH $3,067.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719145
Principal investigator 1 Boehringer Ingelheim International GmbH $4,744.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719147
Principal investigator 1 Boehringer Ingelheim International GmbH $3,825.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719149
Principal investigator 1 Boehringer Ingelheim International GmbH $4,744.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719151
Principal investigator 1 Boehringer Ingelheim International GmbH $4,864.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719153
Principal investigator 1 Boehringer Ingelheim International GmbH $3,825.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719155
Principal investigator 1 Boehringer Ingelheim International GmbH $230.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719157
Principal investigator 1 Boehringer Ingelheim International GmbH $118.00 01/15/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719159
Principal investigator 1 Indivior Inc. $468.55 01/08/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463057
Principal investigator 1 Indivior Inc. $1,003.06 01/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH CENTER
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240462965
Principal investigator 1 Indivior Inc. $12,444.13 01/02/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463021
Principal investigator 1 Indivior Inc. $260.00 01/02/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463023
Principal investigator 1 Indivior Inc. $195.00 01/02/2025 Non-covered Recipient Entity
ERG - MIDWEST CLINICAL RESEARCH CENTER LLC
A PHASE II DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMISED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF INDV-2000 OVER 3 MONTHS IN TREATMENT SEEKING INDIVIDUALS WITH OPIOID USE DISORDER No dispute reported 06/30/2026 1240463025
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 01/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719161
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 01/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719163
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 01/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719165
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 01/01/2025 Non-covered Recipient Entity
Midwest Clinical Research Center
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220719167